Clients will be able to access customized media and improve manufacturing.

Invitrogen introduced its PD-Direct® Bioprocess Services optimized for clinically compliant stem cell culture systems. It will help stem cell therapy developers reduce risks through serum-free production systems, improve manufacturing productivity, and provide on-demand expertise in stem cell media development, according to the firm.


The science of each stem cell type is different and complex, and off-the-shelf products may not enable therapeutic developers to achieve their goals without significant additional investment, Invitrogen points out.


PD-Direct® stem cell culture services provide identification of substrates and enzymes that support cell growth and passaging, determination of cell nutritional and supplementation needs, optimization of complete media formulations for key performance and cell characteristics, IP management strategies, design of formulations for clinical compliance and supply chain risk mitigation, as well as transfer to GMP formulation and manufacturing.

Previous articleTris Finishes 15,000 Sq. Ft. Expansion
Next articleNanoparticle Corona Determined by Size and Charge rather than Just Material